Research Analysts Issue Forecasts for Imunon Q2 Earnings

Imunon, Inc. (NASDAQ:IMNN) – Analysts at Brookline Capital Markets increased their Q2 2026 earnings per share estimates for shares of Imunon in a report released on Friday, June 5th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will earn ($0.68) per share for the quarter, up from their previous estimate of ($0.69). The consensus estimate for Imunon’s current full-year earnings is ($3.69) per share. Brookline Capital Markets also issued estimates for Imunon’s Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($3.00) EPS and FY2027 earnings at ($3.11) EPS.

A number of other analysts have also recently weighed in on IMNN. Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a research report on Tuesday, April 21st. Maxim Group set a $10.00 price objective on Imunon and gave the company a “buy” rating in a research report on Friday, April 17th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Imunon currently has an average rating of “Hold” and an average target price of $10.00.

Imunon Stock Performance

Imunon stock opened at $2.02 on Wednesday. Imunon has a 1 year low of $1.95 and a 1 year high of $27.65. The firm’s 50-day moving average is $2.65 and its 200-day moving average is $3.19. The company has a market cap of $8.48 million, a P/E ratio of -0.39 and a beta of 1.95.

Imunon (NASDAQ:IMNN) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. DRW Securities LLC boosted its stake in Imunon by 6.9% during the 4th quarter. DRW Securities LLC now owns 58,830 shares of the company’s stock valued at $224,000 after purchasing an additional 3,803 shares in the last quarter. Riverview Capital Advisers LLC boosted its holdings in shares of Imunon by 193.3% in the third quarter. Riverview Capital Advisers LLC now owns 34,364 shares of the company’s stock worth $176,000 after buying an additional 22,649 shares during the period. Finally, Armistice Capital LLC acquired a new stake in Imunon during the 4th quarter valued at $1,017,000. Institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.